CTLA4 and neoplasm: In combination with RMC-4998 and RMC-4550, anti-CTLA-4 extended survival compared with dual-targeted therapy and generated one tumour-free mouse (Fig. 7g), with 3/12 mice manifesting intestinal inflammation while the quadruple combination demonstrated the strongest effect on tumour regressions after 4 weeks of treatment (Fig. 7h) resulting in two tumour-free mice (Fig. 7g).